If confirmed in a larger cohort, this data may lead to recommend the estimation of SMN2/SMN1 expression as early indicator for nusinersen efficacy in adult SMA, which may be a valuable support for the clinical practice, considering the administration route of this therapy. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.